Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

[1]  Ahmet Zehir,et al.  Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Hoff,et al.  Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden , 2018, Medicine.

[3]  R. Claus,et al.  Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial , 2018, Journal of Immunotherapy for Cancer.

[4]  G. Mells,et al.  Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab , 2018, Seminars in oncology.

[5]  H. Moch,et al.  Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. , 2017, Current drug metabolism.

[6]  F. Chang,et al.  Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[7]  J. Lunceford,et al.  PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer , 2017, Clinical Cancer Research.

[8]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[9]  F. Hodi,et al.  Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. , 2015, European journal of radiology.

[10]  T. Choueiri,et al.  Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. , 2015, The Lancet. Oncology.

[11]  G. Freeman,et al.  Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study , 2015, Journal of Immunotherapy for Cancer.

[12]  Sarah DiGiulio.  ASCO Releases First Guidelines on Survivorship Care , 2014 .

[13]  C. Wood,et al.  Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. , 2013, European journal of endocrinology.

[14]  Larissa V Furtado,et al.  Adrenocortical carcinoma is a lynch syndrome-associated cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Dieleman,et al.  Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. , 2013, European journal of cancer.

[16]  J. Dieleman,et al.  Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993 , 2013 .

[17]  H X Chen,et al.  Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma , 2013, British Journal of Cancer.

[18]  M. Fassnacht,et al.  Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. , 2012, The Journal of clinical endocrinology and metabolism.

[19]  C. Schade-Brittinger,et al.  Combination chemotherapy in advanced adrenocortical carcinoma. , 2012, The New England journal of medicine.

[20]  S. Roman,et al.  Adrenocortical carcinoma , 2006, Current opinion in oncology.

[21]  L. Dogliotti,et al.  Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma , 1998, Cancer.

[22]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[23]  S. Jolly,et al.  Adrenocortical Carcinoma , 2010, Cancers.

[24]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..